61/120
2.5 / 5 stars
All 120 Win/Lose results shown below
BMRN Roast Me summary
BIOMARIN PHARMACEUTICAL INC (BMRN). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Win.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseBMRN / S&P 1.29% / 15.20% |
LoseBMRN / S&P 11.20% / 15.00% |
LoseBMRN / S&P -89.05% / 50.40% |
| 2026-Q10/3 |
LoseBMRN / S&P -4.95% / -4.33% |
LoseBMRN / S&P 9.90% / 11.30% |
LoseBMRN / S&P -49.26% / 27.70% |
| 2025-Q42/3 |
WinBMRN / S&P 9.73% / 2.65% |
WinBMRN / S&P 12.87% / 9.00% |
LoseBMRN / S&P -18.55% / 13.40% |
| 2025-Q32/3 |
LoseBMRN / S&P -1.47% / 8.12% |
WinBMRN / S&P 12.39% / 4.61% |
WinBMRN / S&P 60.84% / 13.45% |
| 2025-Q22/3 |
LoseBMRN / S&P -22.24% / 10.94% |
WinBMRN / S&P 18.36% / 4.83% |
WinBMRN / S&P 156.06% / 10.63% |
| 2025-Q13/3 |
WinBMRN / S&P 7.55% / -4.27% |
WinBMRN / S&P 19.36% / 4.98% |
WinBMRN / S&P 154.72% / 10.57% |
| 2024-Q42/3 |
LoseBMRN / S&P -6.49% / 2.41% |
WinBMRN / S&P 17.97% / 5.25% |
WinBMRN / S&P 154.02% / 6.15% |
| 2024-Q32/3 |
LoseBMRN / S&P -14.62% / 5.89% |
WinBMRN / S&P 19.14% / 5.89% |
WinBMRN / S&P 115.58% / 6.11% |
| 2024-Q22/3 |
LoseBMRN / S&P -5.74% / 4.28% |
WinBMRN / S&P 15.83% / 5.38% |
WinBMRN / S&P 153.85% / 5.12% |
| 2024-Q12/3 |
LoseBMRN / S&P -9.42% / 10.56% |
WinBMRN / S&P 13.74% / 5.71% |
WinBMRN / S&P 178.95% / 5.59% |
| 2023-Q42/3 |
LoseBMRN / S&P 8.97% / 11.69% |
WinBMRN / S&P 15.42% / 6.81% |
WinBMRN / S&P 16.00% / 7.78% |
| 2023-Q33/3 |
WinBMRN / S&P 2.08% / -3.27% |
WinBMRN / S&P 15.05% / 7.52% |
WinBMRN / S&P 83.33% / -5.03% |
| 2023-Q22/3 |
LoseBMRN / S&P -10.86% / 8.74% |
WinBMRN / S&P 16.89% / 9.50% |
WinBMRN / S&P 100.00% / -8.57% |
| 2023-Q12/3 |
LoseBMRN / S&P -6.04% / 7.50% |
WinBMRN / S&P 15.61% / 10.77% |
WinBMRN / S&P 111.11% / -15.69% |
| 2022-Q42/3 |
WinBMRN / S&P 22.08% / 7.56% |
WinBMRN / S&P 13.53% / 11.88% |
LoseBMRN / S&P BMRN unavailable / -17.99% |
| 2022-Q32/3 |
WinBMRN / S&P 2.29% / -4.88% |
LoseBMRN / S&P 8.64% / 13.47% |
WinBMRN / S&P 500.00% / -1.41% |
| 2022-Q21/3 |
WinBMRN / S&P 7.48% / -16.10% |
LoseBMRN / S&P -0.26% / 13.71% |
LoseBMRN / S&P -93.93% / 11.04% |
| 2022-Q10/3 |
LoseBMRN / S&P -12.73% / -4.60% |
LoseBMRN / S&P 1.91% / 15.97% |
LoseBMRN / S&P -95.56% / 42.23% |
| 2021-Q41/3 |
WinBMRN / S&P 14.31% / 11.03% |
LoseBMRN / S&P -0.76% / 15.00% |
LoseBMRN / S&P -107.78% / 96.40% |
| 2021-Q30/3 |
LoseBMRN / S&P -7.37% / 0.58% |
LoseBMRN / S&P -0.76% / 10.77% |
LoseBMRN / S&P -98.40% / 69.42% |
| 2021-Q22/3 |
WinBMRN / S&P 10.50% / 8.55% |
LoseBMRN / S&P 3.76% / 6.58% |
WinBMRN / S&P 538.81% / 51.81% |
| 2021-Q12/3 |
LoseBMRN / S&P -13.89% / 6.17% |
WinBMRN / S&P 2.16% / -1.06% |
WinBMRN / S&P 553.23% / 7.39% |
| 2020-Q42/3 |
WinBMRN / S&P 15.26% / 12.15% |
WinBMRN / S&P 9.18% / -3.72% |
LoseBMRN / S&P BMRN unavailable / -33.42% |
| 2020-Q31/3 |
LoseBMRN / S&P -38.32% / 8.93% |
WinBMRN / S&P 16.22% / -2.04% |
LoseBMRN / S&P BMRN unavailable / -27.10% |
| 2020-Q22/3 |
WinBMRN / S&P 45.96% / 20.54% |
WinBMRN / S&P 20.46% / -0.46% |
LoseBMRN / S&P BMRN unavailable / -27.11% |
| 2020-Q12/3 |
WinBMRN / S&P -0.06% / -19.60% |
WinBMRN / S&P 18.89% / 3.47% |
LoseBMRN / S&P BMRN unavailable / -14.75% |
| 2019-Q42/3 |
WinBMRN / S&P 25.45% / 9.07% |
WinBMRN / S&P 14.27% / 5.36% |
LoseBMRN / S&P BMRN unavailable / 2.99% |
| 2019-Q31/3 |
LoseBMRN / S&P -21.31% / 1.70% |
WinBMRN / S&P 7.12% / 5.02% |
LoseBMRN / S&P BMRN unavailable / 0.21% |
| 2019-Q20/3 |
LoseBMRN / S&P -3.58% / 4.30% |
LoseBMRN / S&P 6.58% / 6.64% |
LoseBMRN / S&P BMRN unavailable / 8.65% |
| 2019-Q11/3 |
LoseBMRN / S&P 4.32% / 13.65% |
WinBMRN / S&P 9.77% / 8.12% |
LoseBMRN / S&P BMRN unavailable / 14.29% |
| 2018-Q42/3 |
WinBMRN / S&P -12.19% / -13.52% |
WinBMRN / S&P 13.52% / 9.05% |
LoseBMRN / S&P BMRN unavailable / 18.23% |
| 2018-Q31/3 |
LoseBMRN / S&P 2.94% / 7.71% |
WinBMRN / S&P 19.19% / 10.21% |
LoseBMRN / S&P BMRN unavailable / 19.06% |
| 2018-Q22/3 |
WinBMRN / S&P 16.20% / 3.43% |
WinBMRN / S&P 19.78% / 9.03% |
LoseBMRN / S&P BMRN unavailable / 14.46% |
| 2018-Q11/3 |
LoseBMRN / S&P -9.08% / -0.76% |
WinBMRN / S&P 16.85% / 7.68% |
LoseBMRN / S&P BMRN unavailable / 12.46% |
| 2017-Q41/3 |
LoseBMRN / S&P -4.19% / 6.64% |
WinBMRN / S&P 17.62% / 7.03% |
LoseBMRN / S&P BMRN unavailable / 13.82% |
| 2017-Q31/3 |
LoseBMRN / S&P 2.48% / 4.48% |
WinBMRN / S&P 20.17% / 5.68% |
LoseBMRN / S&P BMRN unavailable / 17.57% |
| 2017-Q22/3 |
WinBMRN / S&P 3.46% / 3.09% |
WinBMRN / S&P 23.36% / 4.83% |
LoseBMRN / S&P BMRN unavailable / 17.74% |
| 2017-Q11/3 |
LoseBMRN / S&P 5.96% / 6.07% |
WinBMRN / S&P 28.16% / 3.67% |
LoseBMRN / S&P BMRN unavailable / 13.32% |
| 2016-Q41/3 |
LoseBMRN / S&P -10.46% / 3.82% |
WinBMRN / S&P 25.50% / 2.09% |
LoseBMRN / S&P BMRN unavailable / 7.05% |
| 2016-Q32/3 |
WinBMRN / S&P 18.92% / 3.85% |
WinBMRN / S&P 17.12% / 0.20% |
LoseBMRN / S&P BMRN unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | BMRN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 10.92% | 20.78% |
| Annualized return | 10.92% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | BMRN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -23.31% | 83.14% |
| Annualized return | -5.17% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | BMRN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -32.10% | 319.30% |
| Annualized return | -3.80% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |